AstraZeneca is a global biopharmaceutical company with several leading pharmaceutical products. In 2024, AstraZeneca’s top pharmaceutical product by revenue was Farxiga, a medication used in the treatment of type 2 diabetes mellitus. In the same year, Tagrisso, a cancer drug, generated around *** billion U.S. dollars in revenue for the company.
AstraZeneca company profile
AstraZeneca is a global pharmaceutical company with many employees all over the world. As of 2024, the highest proportion of AstraZeneca’s employees was based in Europe. The global office and corporate headquarters of AstraZeneca is located in Cambridge, UK. In 2024, emerging markets and the U.S. market accounted for the highest revenues for AstraZeneca. The company is also a global leader in pharmaceutical research and development.
AstraZeneca’s R&D
AstraZeneca has many research and development programs that are focused on several therapeutic areas, like oncology, cardiovascular, renal and metabolic diseases, and respiratory disease. AstraZeneca’s research and development expenditures have increased recently. In 2024, over ** percent of AstraZeneca’s total revenue was spent on research and development. As of 2024, AstraZeneca was among the world’s top three pharmaceutical companies according to the number of drugs they had under development at that time.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
AstraZeneca, & U.S. Securities and Exchange Commission. (February 17, 2025). Select leading products of AstraZeneca based on revenue in 2023 and 2024 (in million U.S. dollars) [Graph]. In Statista. Retrieved June 28, 2025, from https://www.statista.com/statistics/267807/astrazeneca-top-products-based-on-revenue/
AstraZeneca, und U.S. Securities and Exchange Commission. "Select leading products of AstraZeneca based on revenue in 2023 and 2024 (in million U.S. dollars)." Chart. February 17, 2025. Statista. Accessed June 28, 2025. https://www.statista.com/statistics/267807/astrazeneca-top-products-based-on-revenue/
AstraZeneca, U.S. Securities and Exchange Commission. (2025). Select leading products of AstraZeneca based on revenue in 2023 and 2024 (in million U.S. dollars). Statista. Statista Inc.. Accessed: June 28, 2025. https://www.statista.com/statistics/267807/astrazeneca-top-products-based-on-revenue/
AstraZeneca, and U.S. Securities and Exchange Commission. "Select Leading Products of Astrazeneca Based on Revenue in 2023 and 2024 (in Million U.S. Dollars)." Statista, Statista Inc., 17 Feb 2025, https://www.statista.com/statistics/267807/astrazeneca-top-products-based-on-revenue/
AstraZeneca & U.S. Securities and Exchange Commission, Select leading products of AstraZeneca based on revenue in 2023 and 2024 (in million U.S. dollars) Statista, https://www.statista.com/statistics/267807/astrazeneca-top-products-based-on-revenue/ (last visited June 28, 2025)
Select leading products of AstraZeneca based on revenue in 2023 and 2024 (in million U.S. dollars) [Graph], AstraZeneca, & U.S. Securities and Exchange Commission, February 17, 2025. [Online]. Available: https://www.statista.com/statistics/267807/astrazeneca-top-products-based-on-revenue/
